TransCode Therapeutics, Inc.
RNAZ
$6.73
-$0.27-3.86%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 21.33% | 49.26% | -18.56% | -37.80% | 98.09% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 42.16% | 110.64% | -17.46% | -3.58% | 24.28% |
| Operating Income | -42.16% | -110.64% | 17.46% | 3.58% | -24.28% |
| Income Before Tax | -123.41% | -109.19% | 17.61% | -263.27% | -44.73% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -127.23% | -109.19% | 17.61% | -263.27% | -44.73% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -127.23% | -109.19% | 17.61% | -263.27% | -44.73% |
| EBIT | -42.16% | -110.64% | 17.46% | 3.58% | -24.28% |
| EBITDA | -41.57% | -111.98% | 17.20% | 3.04% | -24.99% |
| EPS Basic | 94.14% | 96.01% | -- | -- | -- |
| Normalized Basic EPS | 97.65% | 96.01% | -- | -- | -- |
| EPS Diluted | 94.14% | 96.01% | -- | -- | -- |
| Normalized Diluted EPS | 97.65% | 96.01% | -- | -- | -- |
| Average Basic Shares Outstanding | 4,227.49% | 5,143.40% | -- | -- | -- |
| Average Diluted Shares Outstanding | 4,227.49% | 5,143.40% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |